Marion Lepelley
Research Subjects
Marion Lepelley has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Leary
Department of Medical Oncology, Gustave Roussy, Villejuif, France
27 shared publications - Alexis Genthon
Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France
27 shared publications - Amine Belhabri
Centre Leon Berard, Lyon, France, Lyon, France
27 shared publications - Arnaud Pagès
Department of biostatistics, Gustave Roussy, Villejuif, France
27 shared publications - Christian Récher
CHU de Toulouse, Toulouse, France
27 shared publications - Christophe Marzac
Gustave Roussy, Villejuif, France
27 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Commutation plot visualizing the mutated genes in t-MN after OC according to PARPi treatment.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Commutation plot visualizing the mutated genes in t-MN after OC according to PARPi treatment.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
TP53 mutations characteristics among t-MN PARPi national cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
TP53 mutations characteristics among t-MN PARPi national cohort.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Flow chart of the study displaying the three cohorts.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Flow chart of the study displaying the three cohorts.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Waffle chart (%) of patients addressed for cytopenia exploration after OC exposed to a PARPi treatment from cytopenia diagnosis (A) and cytopenia diagnosis based on NGS results (B). Dot plots (C) showing the median WBC, hemoglobin, and platelet counts from patients referred for cytopenia exploration after OC exposed to a PARPi treatment according to t-MN diagnosis (“t-MN”) or not (“Cytopenia”).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Waffle chart (%) of patients addressed for cytopenia exploration after OC exposed to a PARPi treatment from cytopenia diagnosis (A) and cytopenia diagnosis based on NGS results (B). Dot plots (C) showing the median WBC, hemoglobin, and platelet counts from patients referred for cytopenia exploration after OC exposed to a PARPi treatment according to t-MN diagnosis (“t-MN”) or not (“Cytopenia”).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Blood smear and bone marrow aspiration of patient referred for cytopenia post PARPi.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Blood smear and bone marrow aspiration of patient referred for cytopenia post PARPi.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Patient characteristics of the national cohort according to the type of PARPi received (olaparib vs. other PARP inhibitors).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Patient characteristics of the national cohort according to the type of PARPi received (olaparib vs. other PARP inhibitors).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Univariate analysis for overall survival from t-MN diagnosis of patients from the national cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Univariate analysis for overall survival from t-MN diagnosis of patients from the national cohort.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Univariate analysis for overall survival from t-MN diagnosis of patients diagnosed with t-MN after OC according to PARPi exposure.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Univariate analysis for overall survival from t-MN diagnosis of patients diagnosed with t-MN after OC according to PARPi exposure.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Flow chart of the study displaying the three cohorts.
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Flow chart of the study displaying the three cohorts.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Blood smear and bone marrow aspiration of patient referred for cytopenia post PARPi.
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Blood smear and bone marrow aspiration of patient referred for cytopenia post PARPi.